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Hepatic insulin resistance is a key contributor to the
pathogenesis of obesity and type 2 diabetes (T2D).
Paradoxically, the development of insulin resistance
in the liver is not universal, but pathway selective,
such that insulin fails to suppress gluconeogenesis
but promotes lipogenesis, contributing to the hyper-
glycemia, steatosis, and hypertriglyceridemia that
underpin the deteriorating glucose control and
microvascular complications in T2D. The molecular
basis for the pathway-specific insulin resistance re-
mains unknown. Here we report that oxidative stress
accompanying obesity inactivates protein-tyrosine
phosphatases (PTPs) in the liver to activate select
signaling pathways that exacerbate disease progres-
sion. In obese mice, hepatic PTPN2 (TCPTP) inacti-
vation promoted lipogenesis and steatosis and
insulin-STAT-5 signaling. The enhanced STAT-5
signaling increased hepatic IGF-1 production, which
suppressed central growth hormone release and
exacerbated the development of obesity and T2D.
Our studies define amechanism for the development
of selective insulin resistance with wide-ranging
implications for diseases characterized by oxidative
stress.
INTRODUCTION
The liver is an essential organ in glucose homeostasis serving to
produce glucose during periods of fasting to prevent hypoglyce-
mia andmaintain brain function and survival. After a meal, insulin
acts in the liver via the insulin receptor (IR) protein-tyrosine
kinase (PTK) to phosphorylate IR substrate-1/2 and activate
the phosphatidylinositol 3-kinase (PI3K)/AKT pathway (Saltieland Kahn, 2001). AKT2, in turn, phosphorylates Forkhead box
protein O1 (Foxo1) and prevents its nuclear translocation,
thereby repressing Foxo1-mediated transcription. The resultant
inhibition of Foxo1-mediated expression of the gluconeogenic
enzymes phosphoenolpyruvate carboxykinase (PEPCK) and
glucose 6-phosphatase (G6P) helps to suppress hepatic glucose
production and prevent postprandial hyperglycemia and
glucose toxicity. Insulin also acts in the liver via AKT2 to promote
sterol-regulatory element-binding protein 1c (SREBP-1c)
expression and processing (Foretz et al., 1999; Leavens et al.,
2009; Li et al., 2010; Lu et al., 2012; Yecies et al., 2011). Pro-
cessed SREBP-1c in turn promotes the transcription of genes
involved in triglyceride (TAG) synthesis, including acetyl-coen-
zyme A carboxylase (ACC), stearoyl-coenzyme A desaturase
(SCD-1), and fatty acid synthase (FAS) (Horton et al., 2002).
Obesity is a key contributor to the development of insulin resis-
tance and T2D (Johnson and Olefsky, 2013). Insulin resistance is
associated with defects or aberrations in signaling downstream
of the IR PTK. In particular, under conditions of insulin resistance,
PI3K/AKT signaling is attenuated, diminishing insulin’smetabolic
effects (Defronzo, 2009; Saltiel and Kahn, 2001). Defective insu-
lin-induced PI3K/AKT signaling has been attributed to various
interrelated factors including intracellular lipid accumulation,
inflammation, ER stress, and oxidative stress (Johnson andOlef-
sky, 2013; Samuel and Shulman, 2012). Hepatic insulin resis-
tance is thought to be an early event in the development of
T2D (Michael et al., 2000; Turner et al., 2013). The diminished in-
sulin-induced suppression of hepatic gluconeogenesis contrib-
utes to the fasting hyperglycemia evident in patients with T2D.
Paradoxically, insulin-induced lipid synthesis in the liver is not
diminished, but rather elevated in the insulin-resistant state,
exacerbating hepatic steatosis (Biddinger et al., 2008; Brown
and Goldstein, 2008; Haas et al., 2012; Leavens et al., 2009).
Although the basis for the apparent selective insulin resistance
and the contrary effects on hepatic gluconeogenesis versus
lipogenesis in obesity and T2D remain to be resolved, the bifur-
cation of insulin signaling appears to be downstream of AKT2
(Leavens et al., 2009). De novo lipogenesis also occurs viaCell Metabolism 20, 85–102, July 1, 2014 ª2014 Elsevier Inc. 85
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after feeding. Dietary fatty acids and the flux of peripheral fats
from white adipose tissue to the liver can also drive steatosis.
Increased lipogenesis and TAG accumulation can, in turn, result
in increased very-low-density lipoprotein secretion and uptake in
muscle, which exacerbates the development of insulin resis-
tance and contributes to the cardiovascular complications of
the disease (Postic and Girard, 2008; Samuel and Shulman,
2012).
Chronic reactive oxygen species (ROS) generation and oxida-
tive stress occur in a wide variety of human diseases, including
obesity and T2D (Newsholme et al., 2007). Superoxide (O2d
) is
a natural byproduct of mitochondrial oxidative phosphorylation,
but under normal conditions this is rapidly converted to
hydrogen peroxide (H2O2) by superoxide dismutase. H2O2 is
thereon eliminated by antioxidant enzymes such catalase, per-
oxiredoxins, and glutathione peroxidase 1 (Gpx1) (Fisher-Well-
man and Neufer, 2012). In obesity, the chronic uptake and oxida-
tion of energy substrates, particularly lipids, is thought to result in
enhancedmitochondrial O2d
 and H2O2 generation (Fisher-Well-
man and Neufer, 2012). ER stress and the unfolded protein
response in obesity and the increased expression and activation
of NADPH oxidases (NOXs) contribute further to ROS generation
(Furukawa et al., 2004; Jiang et al., 2011). Compelling evidence
links oxidative stress to the promotion of insulin resistance in hu-
mans and rodents (Anderson et al., 2009; Furukawa et al., 2004;
Houstis et al., 2006), and oxidative stress in the liver exacerbates
inflammation and hepatic fibrosis (Paik et al., 2011; Rolo et al.,
2012).
PTPs are important targets for ROS (Tiganis, 2011). Classical
tyrosine-specific PTPs contain a conserved signature motif
([I/V]HCSXGXGR[S/T]G) in their catalytic domains wherein the
invariant Cys is essential for catalytic activity. The low pKa of
the active site Cys facilitates nucleophilic attack of the substrate
phosphotyrosine, but also renders PTPs highly susceptible to
oxidation by ROS such as H2O2 (Tiganis, 2011). Oxidation of
the active site Cys abrogates its nucleophilic properties and in-
duces conformational changes that inhibit PTP activity and pre-
vent substrate binding. PTP oxidation is thought to occur under
both physiological and pathological conditions to promote tyro-
sine phosphorylation-dependent signaling (Tiganis, 2011).
Here we report that oxidative stress in high-fat diet-induced
obesity results in pronounced hepatic PTP oxidation. In partic-
ular, we demonstrate that under conditions of obesity and insulin
resistance, when the PI3K/AKT pathway is otherwise attenuated,
PTPN2 (also known as T cell PTP: TCPTP) is oxidized and inac-
tivated to promote lipogenesis and insulin-induced STAT-5
signaling. We report that the selective activation of the insulin-
STAT-5 pathwaymay be instrumental in the promotion of obesity
through the STAT-5 transcriptional target insulin-like growth fac-
tor-1 (IGF-1) and the repression of growth hormone (GH) release
from the pituitary. Our studies have defined a liver-centric mech-
anism contributing to the development of obesity and T2D.
RESULTS
Hepatic PTP Oxidation in High-Fat-Fed Mice
Obesity is associated with systemic oxidative stress in both hu-
mans and rodents (Furukawa et al., 2004). To determine whether86 Cell Metabolism 20, 85–102, July 1, 2014 ª2014 Elsevier Inc.diet-induced obesity promotes the oxidation of hepatic PTPs,
age-matched C57BL/6 mice were fed either a high-fat diet
(23% fat) or standard chow diet for 24 weeks, and oxidative
stress and PTP oxidation were assessed. Consistent with the
development of oxidative stress, blood oxidized glutathione
(GSSG) levels were increased and the reduced glutathione
(GSH):GSSG ratio was decreased in mice rendered obese by
high-fat feeding when compared with chow-fed lean controls
(Figure 1A). The systemic oxidative stress was, in turn, associ-
ated with increased H2O2 production by hepatocytes (measured
in live cells using the H2O2-selective probe Amplex red) isolated
from high-fat-fed (HFF) versus chow-fed mice (Figure 1B); H2O2
production by hepatocytes from HFF mice was significantly
higher than that occurring in insulin-stimulated hepatocytes (Fig-
ure 1B). To assess whether PTPs may be oxidized in the livers of
HFF mice, we took advantage of a monoclonal antibody (PTPox)
raised against the signature motif peptide of PTP1B with its cat-
alytic cysteinyl residue oxidized to the irreversible sulfonic acid
(Persson et al., 2005). Previous studies have established that
this antibody can detect virtually all classical tyrosine-specific
PTPs when they are oxidized to the sulfonic (SO3H) state (Kar-
isch et al., 2011). H2O2 promotes the reversible oxidation of PTPs
to the sulfenic (SOH) state, which is accompanied in many
classical PTPs by the formation of a sulfenylamide intermediate
that limits further oxidation to the irreversible sulfinic (SO2H)
and SO3H states. At first, we monitored the oxidation status
of PTPs by immunoblot analysis (Figure 1C). Livers from HFF
obese and chow-fed lean mice were homogenized in an anaer-
obic chamber in the presence of N-ethylmaleimide (NEM) to pre-
vent postlysis oxidation and to alkylate all reduced and active
PTPs. Reversibly oxidized PTPs were reduced and hyperoxi-
dized to the SO3H state for detection with PTPox by immuno-
blot analysis. We noted an increase in the oxidation status of
several PTPs in the livers from HFF mice (Figure 1C); PTP oxida-
tion was largely reversible, as several PTPox species were either
not detected or decreased when NEM-treated tissue extracts
were immunoblotted without further processing (Figure S1A).
Oxidized hepatic PTPs in HFF mice included those comigrating
with the prototypic PTP1B (PTPN1) and the closely related
TCPTP (PTPN2), both of which have been implicated in the regu-
lation of hepatic insulin sensitivity and gluconeogenesis (Tiganis,
2013). PTP oxidation was not increased further when HFF mice
were administered insulin, and hepatic PTP oxidation was not
altered in chow-fed mice subjected to hyperinsulinemic-eugly-
cemic clamps (insulin infused for 4 hr; Figures S1B and S1C).
Thus, we propose that the heightened hepatic PTP oxidation in
obese mice occurs as a consequence of the systemic oxidative
stress and the elevated ROS production in the liver parenchyma.
Hepatocytes constitute roughly 80% of the liver volume, with
the remainder comprised of nonparenchymal cells including
Kupffer cells, endothelial cells, and stellate cells. We determined
whether the increased PTP oxidation in the livers of HFF mice
could be ascribed to changes in the oxidation status of PTPs
in hepatocytes. PTP oxidation was assessed in hepatocytes
that were freshly isolated from chow-fed versus HFF mice (Fig-
ure 1D); several PTPox species were increased in hepatocytes
from HFF mice (Figure 1D). Thus, the increased PTP oxidation
in livers of HFF mice may, at least in part, be due to changes in
PTP oxidation in hepatocytes.
Figure 1. Oxidative Stress and Hepatic PTP Oxidation
(A) Eight-week-old male C57BL/6 mice were chow-fed or HFF for 24 weeks. Blood GSH and GSSG levels and GSH:GSSG ratios were determined.
(B) Hepatocytes from 12 week chow-fed or HFF mice were either left untreated or serum-starved and stimulated with 100 nM insulin for 30 min and H2O2
production measured.
(C–F) Livers from 24week chow-fed or HFFmice were processed for an assessment of total PTP oxidation by (C) immunoblot analysis with the PTPox antibody or
(E) mass spectrometry determining relative PTP oxidation (PTP-SO3H), or (F) processed for immunoblot analysis for the indicated PTPs. (D) Hepatocytes were
processed immediately after isolation for an assessment of total PTP oxidation. In (C) and (D), arrows correspond to TCPTP. Results are means ± SEM for the
indicated number of mice (A, E, F) or experimental repeats (B).
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oxidized in HFF obese versus chow-fed, lean mice, we utilized
a recently developed, quantitative proteomic method for the
global assessment of classical PTP oxidation (Karisch et al.,2011). In this approach, hyperoxidized PTPs are digested, en-
riched by PTPox immunoprecipitation, and quantified by mass
spectrometry (Karisch et al., 2011). Using this approach, 6 of
17 known nonreceptor and 9 of 21 known receptor PTPs wereCell Metabolism 20, 85–102, July 1, 2014 ª2014 Elsevier Inc. 87
(legend on next page)
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tected in chow-fed and HFF livers, only 8 exhibited an increase
in their oxidation status in HFF mice (Figure 1E). These included
the nonreceptor phosphatases TCPTP (PTPN2) and PTP1B
(PTPN1) and several transmembrane receptor-type PTPs, in
particular CD45 (PTPRC), which marks hematopoietic cells,
and DEP-1 (PTPRJ), which is expressed in immune and nonim-
mune cells alike (Hermiston et al., 2009). CD45 protein levels
were increased in the livers of HFF mice (Figure 1F), consistent
with the infiltration of immune cells that accompanies hepatos-
teatosis. These results demonstrate that PTPs can be exten-
sively oxidized in vivo in the context of systemic oxidative stress
and raise the possibility that PTP oxidation may contribute to he-
patic pathophysiology in obesity/T2D.
Hepatic STAT-1/STAT-3/STAT-5 Are Hyperactivated
in HFF Mice
Since PTP1B and TCPTP are implicated in liver physiology (De-
libegovic et al., 2009; Fukushima et al., 2010), we focused our
attention on the signaling pathways regulated by these two
phosphatases. TCPTP and PTP1B attenuate both IR signaling
and Janus-activated kinase (JAK)/STAT signaling (Tiganis,
2013). Both PTPs dephosphorylate and inactivate the IR and
JAK family PTKs: PTP1B dephosphorylates JAK-2 and Tyk2
whereas TCPTP dephosphorylates JAK-1 and JAK-3. TCPTP
also dephosphorylates STAT family members (including
STAT-1, STAT-3 and STAT-5) (Tiganis, 2013). To assess the po-
tential impact of hepatic PTP oxidation on cellular signaling and
biological responses in HFF mice, we assessed hepatic IR and
JAK/STAT signaling in liver homogenates from chow-fed versus
HFF mice. JAK/STAT signaling was assessed by monitoring
STAT-1 Y701 (p-STAT-1), STAT-3 Y705 (p-STAT-3), and
STAT-5 Y694 (p-STAT-5) phosphorylation. We found that
p-STAT-1 and p-STAT-3 were elevated in liver homogenates
from HFF (24 week) fasted mice (Figure 2A; Figure S2A); basal
p-STAT-5 was also elevated with more prolonged (40 week)
high-fat feeding (Figure S2A). By contrast, we noted no overt dif-
ferences in general tyrosine phosphorylation in liver homoge-
nates from fasted (4 hr) chow-fed versus HFF mice as assessed
with phospho-tyrosine (p-Tyr)-specific antibodies (Figure S2B).
These results demonstrate that enhanced PTP oxidation per se
does not result in constitutive tyrosine phosphorylation-depen-
dent signaling in fasted livers. In keeping with this, there were
no overt differences in mitogen-activated protein kinase
signaling, as assessed with antibodies to phosphorylated
ERK1/2, nor any increase in basal IR b-subunit Y1162/Y1163Figure 2. Oxidative Stress Promotes Insulin-Induced STAT-5
(A) Eight-week-oldmaleC57BL/6micewere chow-fedorHFF for 24weeks, fasted
(B) Twenty-week-old male C57BL/6 mice were subjected to hyperinsulinemic-e
processed for immunoblotting or quantitative real-time PCR to measure Igf-1 mR
(C–G) Hepatocytes from chow-fed mice were treated with vehicle or 0.5 mM palm
and processed for immunoblotting (C, E–G). (D) H2O2 production was measured in
inhibitor CMP6 (10 mM), mitoTempol (10 mM), or SS31 (50 mM) for 2 hr. In (F), hep
palmitate treatment.
(H and I) H2O2 production and (I) insulin (100 nM)-induced p-STAT-5 signaling in
(J) Eight-week-old male C57BL/6 mice were HFF for 12 weeks and treated with v
(0.5 mU/g, 10 min), and livers were extracted for immunoblotting.
(K)Gpx1+/+ andGpx1–/–male mice were HFF for 24 weeks, then fasted, and liver
SEM) results are shown.(p-IRb) phosphorylation (Figure 2A; Figure S2A). On the other
hand, basal p-AKT was reduced (Figure 2A), in line with the
development of pathway-specific insulin resistance. These re-
sults are consistent with high-fat diet-induced obesity resulting
in the promotion of STAT-1/STAT-3/STAT-5 signaling.
Selective Activation of Insulin-Induced STAT-5
Signaling
We next assessed the potential impact of hepatic PTP oxidation
on insulin signaling in the liver by comparing responses to bolus
insulin administration (0.65 mU/g, intraperitoneal, 10 min) in
24 week chow-fed versus HFF C57BL/6 mice (Figure 2A). We
monitored for p-IRb, activation of PI3K/AKT signaling with anti-
bodies to Ser-473-phosphorylated AKT, and the activation sta-
tus of STAT-1, STAT-3, and STAT-5 using appropriate phospho-
specific antibodies. IR phosphorylation was not overtly altered,
whereas AKT phosphorylation was reduced consistent with the
development of insulin resistance (Figure 2A). Surprisingly, we
found that insulin-induced p-STAT-5 was robust in the livers
fromHFFmice and not detectable in chow-fed control mice (Fig-
ure 2A). By contrast, although basal p-STAT-1 and p-STAT-3
were elevated in livers from HFF mice, they were not induced
further by insulin (Figure 2A). To determine whether the insulin-
induced activation of the p-STAT-5 pathway was unique to
HFF mice, or whether high-fat feeding and obesity exacerbated
the normal response to insulin, we also challenged 8- to 10-
week-old chow-fed mice with increasing concentrations of insu-
lin and monitored for the status of p-STAT-5. We found that with
higher concentrations of insulin (1.3 mU/g), p-STAT-5 was de-
tected in liver homogenates from chow-fed mice (Figure S2C).
GH acts in the liver via JAK-2 and STAT-5 to increase IGF-1
production (Lichanska and Waters, 2008). As insulin lowers
blood glucose and hypoglycemia can in turn promote the release
of GH from the pituitary (Jaffe et al., 1999), the enhanced insulin-
induced hepatic p-STAT-5 in chow-fed mice (administered
1.3 mU/g insulin) could have been a consequence of enhanced
GH release and signaling. To address this possibility, we sub-
jected chow-fed C57BL/6 mice to hyperinsulinemic-euglycemic
clamps, wherein a high dose of insulin was infused constantly
(60 mU/ml insulin, 10–40 ml/min for 4 hr), while euglycemia was
maintained by the coinfusion of glucose, and assessed GH
levels, p-STAT-5 signaling, and hepatic Igf-1 mRNA levels (Fig-
ure 2B; Figure S1C). It is well established that insulin can mimic
IGF-1 in the suppression of GH release from the anterior pitui-
tary, a negative feedback loop that normally prevents the exces-
sive release of GH (Yamashita and Melmed, 1986). Accordingly,, and injectedwithPBSor insulin, and liverswere processed for immunoblotting.
uglycemic clamps (4 hr). Plasma GH levels were measured and livers were
NA.
itate-BSA. Hepatocytes were serum-starved, stimulated with 100 nM insulin,
live cells. Where indicated, hepatocytes were pretreated with vehicle, the JAK
atocytes were transfected with GFP control or Jak-2-specific siRNAs prior to
Gpx1+/+ and Gpx1–/– hepatocytes.
ehicle or SS31 for 10 days. Mice were fasted and injected with PBS or insulin
s were processed for immunoblotting. Representative and quantified (means ±
Cell Metabolism 20, 85–102, July 1, 2014 ª2014 Elsevier Inc. 89
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(Figure 2B). Despite these lower GH levels, p-STAT-5 was
increased significantly in livers from clamped mice when
compared to saline-infused controls (Figure 2B). Igf-1 levels
also were increased in clamped mice, compared with controls,
and the increase in Igf-1 expression correlated largely with the
degree of p-STAT-5 (Figure 2B; numbers in lanes correspond
to points in panel below). Complementing these in vivo studies,
we found that insulin stimulation also resulted in a modest, but
reproducible increase in STAT-5 activation in isolated primary
hepatocytes from C57BL/6 mice (Figure 2C). Taken together,
these results demonstrate that the insulin-induced p-STAT-5
pathway occurs in hepatocytes to promote the expression of
STAT-5 target genes such as Igf-1 and that the STAT-5 pathway
is exacerbated in HFF obese mice, when insulin-induced PI3K/
AKT signaling is otherwise attenuated.
ROS Promote Insulin-Induced STAT-5 Signaling
Having established that insulin signals via STAT-5 in the liver and
that this is exacerbated in obesity, we next sought to define the
basis for the exacerbation of the IR-STAT-5 pathway in HFF
mice. In particular, we asked whether the hepatic oxidative
stress associated with obesity might inactivate PTPs for the se-
lective promotion of insulin-induced STAT-5 signaling. To this
end we isolated hepatocytes from chow-fed lean mice and as-
sessed the impact of incubating them with the fatty acid palmi-
tate, which promotes insulin resistance and generates high rates
of mitochondrial H2O2 emission (Fisher-Wellman and Neufer,
2012). We found that treatment with palmitate-BSA promoted
H2O2 production and resulted in increased insulin-induced
p-STAT-5 (Figures 2C and 2D). The increase in p-STAT-5 was
accompanied by a decrease in PI3K/AKT signaling (Figure 2C),
consistent with palmitate promoting insulin resistance. The insu-
lin-induced p-STAT-5 in untreated and palmitate-treated hepa-
tocytes was reliant on JAK-2, since a highly selective JAK PTK
inhibitor (Figure 2E), or JAK-2 knockdown using specific
siRNAs (Figure 2F), attenuated insulin-induced p-STAT-5
signaling. To determine if the palmitate-mediated increase in in-
sulin-induced p-STAT-5 was mediated by the increase in
mitochondrial ROS emission, we took advantage of the mito-
chondrial-targeted antioxidant mitoTEMPOL and the mitochon-
drial-targeted peptide SS31 (Bendavia, Stealth Peptides) that
accumulates in mitochondria and reduces mitochondrial
O2,
/H2O2 generation/release (Anderson et al., 2009). We found
that treating hepatocytes with mitoTEMPOL or SS31 signifi-
cantly attenuated the palmitate-induced increase in p-STAT-5
signaling in response to insulin (Figure 2G). Finally, we assessed
whether the oxidation status of PTPs may be increased in
response to palmitate in hepatocytes. For these experiments
we took advantage of nontransformed AML12 hepatocytes.
Treatment of AML12 cells with palmitate increased both H2O2
production and PTP oxidation (Figure S1E).
To further explore the role of H2O2 in the promotion of insulin-
induced p-STAT-5 signaling, we took advantage of mice lacking
the antioxidant enzyme Gpx1, which converts H2O2 to water.
Hepatocytes were isolated from 12-week-old male Gpx1/
and Gpx1+/+ mice, and H2O2 levels and insulin-induced
p-STAT-5 signaling were assessed (Figures 2H and 2I). Gpx1
deficiency resulted in a 2-fold increase in H2O2 production in90 Cell Metabolism 20, 85–102, July 1, 2014 ª2014 Elsevier Inc.hepatocytes (Figure 2H), and this was accompanied by a striking
increase in basal and insulin-induced p-STAT-5 signaling (Fig-
ure 2I), which was increased further when cells were treated
with palmitate (data not shown).
Having established that H2O2 can promote insulin-induced
p-STAT-5 signaling in hepatocytes ex vivo, we next assessed
whether this might occur in vivo. First we determined if the mito-
chondrial-targeted SS31 could attenuate insulin-induced
p-STAT-5 signaling in HFF mice. Mice that had been HFF for
12 weeks were administered vehicle control or SS31
(2.0 mg/kg/day intraperitoneal) for 12 days, and insulin-induced
(0.5 mU/g) STAT-5 signaling was assessed (Figure 2J). Insulin-
induced p-STAT-5 signaling trended lower in SS31-treated
mice (Figure 2J), consistent withmitochondrial-derived oxidative
stress contributing to the promotion of STAT-5 signaling. We
next determined if exacerbating oxidative stress could have
the opposite effect and enhance insulin-induced STAT-5
signaling. For this we took advantage of Gpx1/mice and as-
sessed if Gpx1 deficiency and elevated H2O2 could exacerbate
high-fat diet-induced oxidative stress, PTP oxidation, and
p-STAT-5 signaling (Figures S1F and S1G). Blood GSH:GSSG
ratios in Gpx1–/– versus Gpx1+/+ HFF (24 week) mice were
reduced (Figure S1F), consistent with the promotion of systemic
oxidative stress; alterations in GSH:GSSG ratios were not
evident in chow-fed mice. The increased oxidative stress was
in turn associated with elevated hepatic PTP oxidation (Fig-
ure S1G), as assessed by immunoblot analysis with the PTPox
antibody; the increase in PTP oxidation occurred for several spe-
cies including one comigrating with TCPTP (Figure S1G).
Furthermore, the increased hepatic PTP oxidation coincided
with the detection of hepatic p-STAT-5 in the livers of fasted
Gpx1–/– mice (Figure 2K). Taken together these results provide
evidence for hepatic oxidative stress promoting insulin-induced
hepatic p-STAT-5 signaling in vivo. Moreover, these results are
consistent with the possibility that the ROS-mediated promotion
of insulin-p-STAT-5 signaling might be reliant on the oxidation of
PTPs such as TCPTP.
Hepatic TCPTP Deficiency Exacerbates Obesity,
Steatosis, and Insulin Resistance
To ascertain if the inactivation of hepatic PTPs might contribute
to the promotion of STAT-1, STAT-3, and STAT-5 signaling and
the development of obesity and T2D, we sought to delete those
hepatic PTPs that were oxidized in HFF mice. We focused our
attention on TCPTP for several reasons. First, the relative in-
crease in TCPTP oxidation in HFF obese mice was greater
than that of other nontransmembrane PTPs (Figures 1E and
1F). Second, TCPTP has the capacity to attenuate STAT-5
signaling (Loh et al., 2011), and third, TCPTP has been implicated
in the attenuation of hepatic STAT-3 signaling (Fukushima et al.,
2010). Ptpn2lox/lox (lox/lox) mice were bred with Alb-Cre mice to
generate liver-specific TCPTP knockout (Alb-Cre;Ptpn2lox/lox:
LTKO) mice (Figure S3A). Seven-week-old LTKOmice appeared
normal and did not exhibit differences in body weight/adiposity
or overt alterations in glucose tolerance (data not shown). To
assess the impact of hepatic TCPTP deficiency on the develop-
ment of obesity and T2D, 6-week-old male and female lox/lox
and LTKO mice were fed standard chow versus high-fat diets
for 12 weeks, and their body weights and metabolic status
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male LTKOmice fed a high-fat diet gainedmore weight than their
lox/lox counterparts, and this was associated with increased
adiposity, as assessed by measuring fat pad weights and by
monitoring body composition by dual-energy X-ray absorptiom-
etry (DEXA) (Figures 3A–3H). Although liver weights were higher
in HFF LTKO mice, gross differences in body length were not
evident, and no significant differences were noted in lean mass
or bone density (Figures 3A–3H; data not shown). The increased
adiposity was accompanied by decreased energy expenditure in
both sexes and decreased respiratory exchange ratio (RER) in
male mice (Figure 3I; Figure S4A). No differences were seen
in ambulatory activity (Figure 3I; Figure S4A) or food intake
(data not shown), arguing against overt differences in the central
control of body weight. Increased weight gain and adiposity and
decreased energy expenditure were also observed in female
LTKO mice fed a standard chow diet, but not in chow-fed male
mice (Figures S4B and S4C; data not shown). These results indi-
cate that TCPTP deficiency in the liver promotes diet-induced
weight gain. Moreover, male mice with heterozygous hepatic
TCPTP deficiency (Alb-Cre;Ptpn2lox/+; LTKO HET) also gained
more weight when fed a high-fat diet, and this was associated
with increased adiposity (Figure 3J). Thus, even partial hepatic
TCPTP deficiency, or TCPTP inactivation, as might occur as a
consequence of oxidation, is sufficient to promote obesity. In
keeping with their increased adiposity, HFF LTKO and LTKO
HET mice exhibited decreased insulin sensitivity, as monitored
in insulin tolerance tests, and glucose intolerance, as assessed
in glucose tolerance tests (Figure 3K; Figures S4D, S4E, and
S4G). HFF LTKO mice also exhibited elevated fasting blood
glucose levels, accompanied by elevated plasma insulin levels
in fed (female) and fasted (male and female) mice (Figure 3L; Fig-
ure S4F) and decreased insulin-induced PI3K/AKT signaling in
liver and muscle (Figure 3M; Figures S4H and S4I).
Next we assessed the impact of hepatic TCPTP deletion on
liver morphology (Figure 4A; Figure S5A). As noted earlier, livers
from male and female 12 week HFF LTKO mice were heavier
than their lox/lox counterparts. This was associated with
increased steatosis, as assessed by gross morphology, histol-
ogy (hematoxylin and eosin staining), and oil Red O staining
(stains lipid droplets) and by measuring hepatic lipids (Figures
4A and 4B). The steatotic phenotype was not accompanied by
alterations in circulating free fatty acids (FFAs) and TAGs (Fig-
ure S5B). The increased steatosis was not evident in 20 week
HFF LTKO HET livers (Figure 4C), even though these mice ex-
hibited increased diet-inducedweight gain and insulin resistance
(Figure 3J; Figure S4G). These findings suggest that the promo-
tion of obesity and the development of steatosis in HFF LTKO
mice might be regulated by independent processes.
Steatosis in obesity is accompanied by increased hepatic
levels of the transcription factors SREBP-1c and peroxisome
proliferator-activated receptor g (PPAR-g) (Horton et al., 2002;
Memon et al., 2000). Hepatic overexpression of SREBP-1c or
PPAR-g is sufficient to promote steatosis (Shimano et al.,
1997; Yu et al., 2003), whereas PPAR-g deletion in hepatocytes
can attenuate both genetic and high-fat diet-induced fatty liver
disease (Matsusue et al., 2003; Mora´n-Salvador et al., 2011).
SREBP-1 and PPAR-g were elevated in the livers of HFF male
and female LTKO mice (Figure 4D; Figure S5C), but interestinglynot in HFF LTKO HETmice (Figure 4C; data not shown). SREBP-
1c promotes the expression of lipogenic enzymes such as FAS
and SCD-1 (Horton et al., 2002) and PPAR-g promotes the tran-
scription of fatty acid transporters such as CD36/FAT to promote
the uptake of FFAs (Barclay et al., 2011). SCD-1 and FAS protein
levels were elevated in the livers of HFF male and female LTKO
mice (Figure 4D), as was the expression ofCd36mRNA in female
mice (Figure 4E). Moreover, hepatic lipogenesis, as assessed in
liver slices ex vivo also was increased in HFF LTKO mice (Fig-
ure 4F). Taken together, these results demonstrate that the dele-
tion of TCPTP in the liver promotes diet-induced obesity and
insulin resistance as well as hepatic lipogenesis and steatosis.
Hepatic TCPTP Deficiency Promotes STAT-1/STAT-3/
STAT-5 Signaling
To understand how hepatic TCPTP deletion/inactivation might
be promoting obesity/T2D and steatosis, we sought to delin-
eate the tyrosine phosphorylation-dependent pathways that
might be altered in 12 week HFF LTKO mice and 20 week
LTKO HET mice. We did not observe any significant change
in global tyrosine phosphorylation, basal ERK1/2, or p38 activa-
tion, or in the activation of the ER stress response, as moni-
tored with antibodies to Thr-980 phosphorylated PERK or
Ser-51 phosphorylated eIFa in the livers of fasted mice (Fig-
ure S6A; data not shown). Similarly, TCPTP deficiency did not
result in a global increase in the phosphorylation of TCPTP sub-
strates, including that of Src family kinases (SFKs), as moni-
tored with antibodies to the Y416 site on c-Src (Figure S6A),
and JAK-1, as monitored with antibodies to the Y1022/Y1023
PTK activation loop site (Figure S5F). Thus, hepatic signaling
in fasted mice was not elevated in general as a consequence
of TCPTP deficiency. Previous studies have established that
STAT-1, STAT-3, and STAT-5 may serve as substrates of
TCPTP (Tiganis, 2013; Tiganis and Bennett, 2007). We found
that p-STAT-1, p-STAT-3, and p-STAT-5 were elevated in the
livers of fasted male and female LTKO mice that were HFF
for 12 weeks, when compared to lox/lox controls (Figures 5A
and 5E; Figures S5D and S5E). The elevated STAT-1/STAT-3/
STAT-5 signaling in HFF LTKO liver homogenates was not
associated with overt alterations in the expression of PTP1B,
SHP-1, and SHP-2 (Figure S6B) that have also been implicated
in the control of JAK/STAT signaling. Importantly, interferon
(IFN) g-induced p-STAT-1 was increased in hepatocytes iso-
lated from LTKO mice, p-STAT-3 and STAT-5 were elevated
constitutively in LTKO hepatocytes (Figure 5B), and p-STAT-1
and STAT-5 were elevated in C57BL/6 hepatocytes after
TCPTP knockdown (Figure S6C), consistent with the enhanced
signaling in vivo being hepatocyte intrinsic. Interestingly, only
p-STAT-5 was elevated in the livers of 20 week HFF LTKO
HET mice, highlighting the sensitivity of the STAT-5 pathway
to Ptpn2 gene dosage in the context of obesity (Figure 5C).
Moreover, as p-STAT-1 and p-STAT-5 were not detected in
the livers of 7-week-old chow-fed LTKO male mice (Figure 5D),
these results point toward TCPTP deficiency promoting
p-STAT-1 and p-STAT-5 only in the context of high-fat
feeding/obesity.
Our studies indicate that high-fat feeding of C57BL/6 mice
promotes hepatic insulin-induced p-STAT-5 signaling. Accord-
ingly, we next examined whether the inactivation of hepaticCell Metabolism 20, 85–102, July 1, 2014 ª2014 Elsevier Inc. 91
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the promotion of insulin-induced p-STAT-5 signaling. To this end
we assessed the impact of TCPTP deficiency on hepatic insulin
signaling in mice that had been HFF for 12 weeks (Figure 5E; Fig-
ure S5E). Despite insulin-induced PI3K/AKT signaling being
attenuated in HFF LTKO livers (Figure 3M; Figure S4H), we found
that the induction of p-STAT-5 was significantly enhanced in
male and female LTKO mice (Figure 5E; Figure S5E). Although
IR b-subunit Y1162/Y1163 phosphorylation was elevated in the
livers of fasted HFF LTKO male mice (not female mice), insulin-
induced IR phosphorylation (Figure 5E; Figure S5E) was not
altered by TCPTP deficiency. These results are consistent with
previous studies demonstrating that TCPTP regulates basal
but not insulin-induced IR phosphorylation in the liver (Fukush-
ima et al., 2010). Moreover, while insulin-induced STAT-5
signaling was enhanced in LTKO livers, JAK-1 Y1022/Y1023
(p-JAK-1) and JAK-2 Y1007/Y1008 (p-JAK-2) phosphorylation
was not altered (Figures S5F and S5G). Therefore, these results
are consistent with the induction of STAT-5 signaling in response
to insulin occurring downstream of the IR and JAK PTKs. Taken
together, our results indicate that the inactivation of TCPTP
might contribute to the promotion of basal STAT-1 and STAT-3
signaling and insulin-induced STAT-5 signaling in the context
of obesity and insulin resistance.
Hepatic TCPTP Deficiency Alters the IGF-1/GH Axis
We next explored the potential molecular mechanisms by
which hepatic TCPTP deficiency might promote obesity and
T2D. We noted that p-STAT-5, but not p-STAT-1 or p-STAT-
3, was elevated in the livers of HFF LTKO HET mice (Figure 5D).
Because HFF LTKO HET male mice gained more weight and
exhibited greater insulin resistance than controls, we reasoned
that the enhanced p-STAT-5 might be sufficient to drive the
expression of genes that promote obesity and T2D. In partic-
ular, we focused on two STAT-5 transcriptional targets, Igf-1
(Cui et al., 2007) and the gene encoding pyruvate dehydroge-
nase kinase 4 (Pdk4) (White et al., 2007). PDK4 phosphorylates
pyruvate dehydrogenase complex to conserve glucose and
divert three carbon compounds for gluconeogenesis (Kim
et al., 2012). In keeping with the elevated hepatic p-STAT-5
in HFF LTKO mice, we found that PDK4 protein and Pdk4
mRNA were increased in both male and female mice (Figures
4G and 4H; Figures S5F and S5G). Furthermore, Ptpn2 knock-
down in hepatocytes using siRNAs increased Pdk4 message
(Figure 4I), consistent with the increased PDK4 in vivo being
directly attributable to TCPTP deficiency. Despite the increase
in PDK4, we did not detect any differences in the expression of
the gluconeogenic genes for PEPCK (Pck1) or G6P (G6pc) in
HFF LTKO livers (Figure 4E), nor differences in glucose excur-
sions in response to the gluconeogenic substrate pyruvate
(data not shown), suggesting that hepatic glucose productionFigure 3. Hepatic TCPTP Deletion Promotes Obesity and Insulin Resis
(A–I) Seven-week-old lox/lox and LTKO mice were HFF for 12 weeks and body w
composition (D and H), and oxygen consumption, RER, energy expenditure and
(J) Seven-week-old lox/+ and LTKO HET mice were HFF for 20 weeks, and body
(K and L) HFF mice were subjected to insulin tolerance tests (K), and fed and fas
(M) Fasted HFF mice were injected with insulin, and livers were extracted for im
shown.was not altered. Thus, changes in PDK4 expression may not
be sufficient to influence the development of obesity and insulin
resistance in LTKO mice.
STAT-5 is both necessary and sufficient for the GH-induced
transcription of Igf-1 in the liver (Cui et al., 2007). IGF-1 can in
turn feed back onto hypothalamic neurons and somatotrophs
to inhibit GH release from the pituitary (Romero et al., 2010).
We found that serum IGF-1 levels were increased in male and fe-
male mice fasted overnight (Figure 4J). Moreover, in keeping
with TCPTP’s potential to regulate STAT-5 signaling and Igf-1
expression, we found that Ptpn2 knockdown using siRNAs
increased Igf-1 mRNA expression in C57BL/6 hepatocytes (Fig-
ure 4I). Finally, consistent with circulating IGF-1 levels being
increased, we found that serum GH levels were decreased in fe-
male mice and trended lower in male mice (Figure 4J); the differ-
ence in GH levels is in keeping with the continuous versus pulsa-
tile nature of GH secretion in female versusmalemice (Lichanska
and Waters, 2008). GH levels are reduced in obese rodents and
humans and this can promote fat accumulation (Lichanska and
Waters, 2008). Thus, elevated hepatic STAT-5 signaling associ-
ated with hepatic TCPTP deficiency/inactivation could promote
IGF-1 expression for the suppression of GH release and the pro-
motion of adiposity in nonhepatic tissues.
Hepatic Stat-5 Heterozygosity Corrects Obesity but Not
Steatosis
To assess the importance of hepatic STAT-5 signaling in the
development of obesity and T2D, we determined the effect of
superimposing STAT-5 deficiency on LTKO mice. To this
end we crossed male and female LTKO mice onto a hepatic
Stat-5lox/+ (Cui et al., 2007) background (generating LTKO;
Stat-5lox/+ mice) to specifically reduce STAT-5 in the liver by
50%, and then fed mice a high-fat diet for 12 weeks (Figure 6;
Figure S7A). Remarkably, hepatic Stat-5 heterozygosity largely
corrected the obesity phenotype in LTKO male and female
mice (Figure 6A; Figure S7B). The decreased weight gain in
LTKO;Stat-5lox/+ mice was attributable to decreased adiposity,
as assessed by DEXA and by weighing fad pads, and was
accompanied by increased energy expenditure (Figure 6A; Fig-
ure S7B), but unaltered food intake and activity (data not
shown). Moreover, in female mice the decreased adiposity in
LTKO;Stat-5lox/+ mice was accompanied by improved glucose
homeostasis, as reflected by the reduced fasted blood glucose
levels in females (Figure 6B); fed and fasted plasma insulin levels
also trended lower in both male and female mice (Figure 6C).
Notably, when we assessed p-STAT-5 levels in 4 hr fasted
LTKO;Stat-5lox/+ mice we found that p-STAT-5 approximated
that seen in lox/lox and lox/lox;Stat-5lox/+ controls (Figure 6D).
In keeping with the decreased STAT-5 signaling, we found that
the otherwise increased hepatic PDK4 levels in LTKO mice
were corrected by Stat-5 heterozygosity (Figure 6D), as weretance
eights (A and E), gross morphology (B and F), tissue weights (C and G), body
ambulatory activity (I) were assessed.
weights and composition were determined.
ted blood glucose levels and plasma insulin levels were determined (L).
munoblot analysis. Representative and quantified (means ± SEM) results are
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Figure 4. LTKO Mice Exhibit Steatosis and Alterations in IGF-1 and GH
(A–H)Seven-week-oldmale lox/lox andLTKOor lox/+ andLTKOHETmicewereHFF for 12and20weeks, respectively. Liverswere extracted from fastedmiceand
processed for histology (A and C), lipid analyses (B), immunoblotting (C, D, and G), or real-time PCR (E and H). Lipogenesis was assessed ex vivo in liver slices (F).
(I) Hepatocytes from chow-fed C57BL/6 were transfected with GFP- or Ptpn2-specific (TCPTP#1) siRNAs and, after 48 hr, processed for real-time PCR.
(J) Lox/lox and LTKOmice were HFF for 12 weeks, then fasted overnight, and serum IGF-1 and GH levels were determined. Representative and quantified results
(means ± SEM) results are shown.
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male mice; levels in male mice not determined) (Figures 7A and
7B). Therefore, the heightened STAT-5 signaling in HFF LTKO
mice alters IGF-1 and GH levels and promotes obesity.
In contrast to the effects on obesity, Stat-5 heterozygosity did
not correct the steatotic phenotype evident in HFF LTKO male
mice (Figure 6E); in female HFF LTKO;Stat-5lox/+ mice, steatosis
appeared to be decreased (Figure 6E) and hepatic TAG levels
trended lower, but this was not significant (Figure 6F). Moreover,
p-STAT-1 and p-STAT-3 signaling as well as PPAR-g and
SREBP-1 protein levels remained elevated and were indistin-
guishable from those in LTKOmice (Figure 6D), in line with these
being STAT-5-independent events. Interestingly, we found that
heterozygous Stat-5 deletion alone in the liver (Alb-Cre;
Stat-5lox/+) promoted steatosis and modestly increased
adiposity in HFF mice (Figures S7C–S7E); thus, the decreased
adiposity in HFF LTKO;Stat-5lox/+ mice was not due to an unre-
lated effect of STAT-5 deficiency. The increased adiposity and
steatosis in HFF Alb-Cre;Stat-5lox/+ mice is consistent with the
results of previous studies (Cui et al., 2007). Irrespective, these
results indicate that the promotion of hepatic STAT-5 signaling
in LTKO mice promotes obesity, whereas alternate pathways
promote steatosis.
The Altered IGF-1/GH Axis in LTKO Mice Promotes
Obesity
Having established the importance of STAT-5 signaling in the
development of obesity, we next sought to determine the extent
to which perturbations in the IGF-1/GH axis might contribute to
the obesity phenotype. In particular, we determined if the
elevated IGF-1 and lower GH levels in LTKO mice were respon-
sible for the high-fat diet-induced obesity by asking whether the
promotion of endogenous GH secretion could correct the
increased weight gain (Figures 7C–7E). These studies were un-
dertaken in female mice where GH secretion is continuous,
rather than in male mice where interventions could be
confounded by the pulsatile nature of GH secretion (Lichanska
and Waters, 2008). HFF LTKO mice were administered either
vehicle control or the synthetic GH releasing hormone agonist
JI-38 (Kanashiro-Takeuchi et al., 2010). JI-38 was administered
at the beginning of the light and dark cycles for 20 days and
body weights were monitored every 4–5 days. We found that
JI-38 administration promoted GH release and corrected the
obesity phenotype in LTKO mice, preventing weight gain and
the increase in adiposity without affecting lean mass or bone
density (Figures 7C–7E). Importantly, the effects of JI-38 admin-
istration were reversible, and HFF LTKO mice regained weight
upon cessation of JI-38 administration (data not shown). Taken
together, these results are consistent with the STAT-5/IGF-1/
GH axis playing a pivotal role in the development of obesity in
LTKO mice.
DISCUSSION
It has long been known that the development of insulin resis-
tance in the liver can be pathway selective, such that insulin fails
to suppress gluconeogenesis but promotes lipogenesis, contrib-
uting to the development of fatty liver disease, dyslipidemia, and
atherosclerosis (Brown and Goldstein, 2008). We establish thecapacity of ROS in obesity to inactivate hepatic PTPs for the acti-
vation of select signaling pathways in an otherwise insulin-resis-
tant state. In particular, we demonstrate that ROS inactivate
TCPTP to promote the insulin-STAT-5 pathway and exacerbate
the development of obesity and insulin resistance and thus the
hasten progression toward morbid obesity and T2D. In addition,
our studies suggest that the oxidation of PTPs such as TCPTP in
obesity might also function through independent pathways,
possibly in concert with insulin-induced and AKT2-mediated
signaling (Biddinger et al., 2008; Haas et al., 2012; Leavens
et al., 2009), to promote lipogenesis and the development of fatty
liver disease.
The inhibition of PTPs by ROS is thought to represent a key
mechanism for the regulation of PTP function and the coordina-
tion of tyrosine phosphorylation-dependent cellular signaling (Ti-
ganis, 2011). Cell-based studies have established that the inhibi-
tion of PTPs by ROS such as H2O2 is essential for tyrosine
phosphorylation-dependent signaling in response to growth fac-
tors, cytokines, hormones, and cell adhesion (Tiganis, 2011).
Moreover, increases in H2O2 in muscle, occurring as a conse-
quence of Gpx1 deficiency, can promote insulin signaling in vivo
to attenuate the development of insulin resistance (Loh et al.,
2009). However, to date there is no direct evidence for PTPs be-
ing oxidized in vivo in response to a physiological stimulus. Simi-
larly, although others have reported that PTPs can be oxidized
under pathological conditions in vivo, including ischemia/reper-
fusion injury and hepatocarcinogenesis, evidence for this has
been indirect, relying on the measurement of phosphatase
activity (He et al., 2010; Sandin et al., 2011), or undertaken in
mice with a deficiency in Gpx1 (Merry et al., 2013). Our studies
directly assess the oxidation status of PTPs in the context of
an important disease, demonstrating that classical PTPs in the
liver undergo substantial oxidation in obese mice characterized
by systemic and hepatic oxidative stress. Prominent nontrans-
membrane PTPs undergoing oxidation included PTP1B and
TCPTP. The differential oxidation of PTPs may result from
intrinsic differences in PTP sensitivity to oxidation (Lou et al.,
2008; Ross et al., 2007) and/or reflect differences in PTP versus
antioxidant enzyme subcellular localizations.
Notably, the oxidation of such PTPs did not result in global in-
creases in tyrosine phosphorylation in fasted mice. Although we
cannot exclude additional tyrosine phosphorylation-dependent
pathways being elevated in response to specific stimuli, our find-
ings are consistent with hepatic PTP oxidation in HFF mice pro-
moting the activation of select signaling pathways. In particular,
we found that basal p-STAT-1, p-STAT-3, and insulin-induced
p-STAT-5 were increased in the livers of HFF mice. This is in
keeping with TCPTP being one of the most abundantly oxidized
PTPs in the livers of HFF mice and TCPTP’s capacity to dephos-
phorylate STAT family members (Tiganis, 2013; Tiganis and Ben-
nett, 2007). Although in this study we focused our attention on
TCPTP, it is probable that the oxidation of multiple PTPs contrib-
utes to the promotion of hepatic STAT-1/STAT-3/STAT-5
signaling in obesity. Previous studies have reported that
STAT-5 can interact directly with the IR and that the IR directly
or indirectly via JAK-2 can phosphorylate and activate STAT-5
in cell lines (Chen et al., 1997; Le et al., 2002). Our results indicate
that JAK-2 is essential for the ROS-mediated and insulin-
induced activation of STAT-5 in hepatocytes. We speculateCell Metabolism 20, 85–102, July 1, 2014 ª2014 Elsevier Inc. 95
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of HFFmicemight promote the coordinated activation of hepatic
JAK-2 and STAT-5 in response to insulin. This is in keeping with
previous studies that have shown that PTP1B and TCPTP can
function in concert to attenuate hypothalamic JAK-2/STAT-3
signaling in vivo (Loh et al., 2011). Although liver-specific
PTP1B deficiency does not promote obesity (Delibegovic et al.,
2009), PTP1B knockout mice fed a high-fat diet for 19.5 weeks
are more steatotic than controls (Miraldi et al., 2013). Thus the
oxidation of PTP1B and TCPTP may at least cooperate in the
promotion of steatosis.
Our studies indicate that the selective activation of the insulin-
STAT-5 pathway in the livers of HFF/obesemice was attributable
to the accompanying oxidative stress, since (1) palmitate-
induced mitochondrial H2O2 generation in isolated hepatocytes
enhanced insulin-induced p-STAT-5, while repressing PI3K/
AKT signaling; (2) basal and insulin-induced p-STAT-5 were
exacerbated by the increased H2O2 accompanying Gpx1 defi-
ciency; and (3) insulin-induced hepatic p-STAT-5 in HFF mice
was at least partially attenuated by SS31. It remains unclear if
mitochondria are solely responsible for the ROS generation,
PTP oxidation, and promotion of p-STAT-5 in HFF mice.
Increased NOX activity and expression can contribute to hepatic
ROS generation in the fibrotic liver (Aoyama et al., 2012; Paik
et al., 2011), but it remains to be seen if NOXs contribute to he-
patic oxidative stress in obesity.
Aberrations in the IGF-1/GH axis have been implicated in the
development of obesity. GH levels are markedly reduced in
obese humans, with lower GH levels correlating with increased
visceral adiposity (Rasmussen, 2010). Similarly, GH deficiency
(Donahue and Beamer, 1993) and defects in GH receptor-
STAT-5 signaling (Rowland et al., 2005) in mice are associated
with the development of obesity. The precise mechanisms by
which decreased GH levels contribute to obesity are not fully
understood, but may be attributable to defective lipolytic re-
sponses and decreased fatty acid oxidation (Lichanska andWa-
ters, 2008). In humans the increased adiposity may also be due
to decreases in energy expenditure (Møller and Jørgensen,
2009; Snel et al., 1995; Wolthers et al., 1996). This is consistent
with the decreased energy expenditure seen in HFF LTKO mice;
although corrected by Stat-5 heterozygosity, it remains to be
determined if the effects on energy expenditure were mediated
by the IGF-1/GH axis. The underlying cause(s) of the lower GH
levels in human obesity is/are contentious and include the sup-
pression of GH secretion by elevated plasma insulin (Steyn
et al., 2013) and IGF-1 (Romero et al., 2010). Total plasma IGF-
1 is not reduced to the degree predicted by the low GH levels,
and circulating IGF-1 is in the normal-high range in obese hu-
mans (Frystyk et al., 1999; Nam et al., 1997). The association be-
tween IGF-1 and GH is especially evident in adolescent obesity,
where physiological insulin resistance and elevated circulatingFigure 5. Hepatic TCPTP Deletion Exacerbates Insulin-Induced STAT-
(A) Seven-week-old male lox/lox and LTKO mice were HFF for 12 weeks. Livers
(B) Hepatocytes were serum-starved and stimulated with either 50 U/ml INF-g, 1
(C) Seven-week-old male lox/+ and LTKO HET mice were HFF for 20 weeks. Liv
(D) Livers from 7-week-old fasted male lox/lox and LTKO mice were processed
(E) Seven-week-old male lox/lox and LTKOmice were HFF for 12 weeks, fasted, a
Representative and quantified (means ± SEM) results are shown.IGF-1 (Moran et al., 2002) are exaggerated and associated
with decreased GH levels (Vanderschueren-Lodeweyckx,
1993). Our studies indicate that the oxidative stress and the inac-
tivation of hepatic PTPs in obesity might promote the insulin-
STAT-5-IGF-1 pathway to reduce GH levels and exacerbate
the development of obesity and T2D. Our studies also provide
a potential explanation for the enhanced growth rates seen in
obese children, where the hyperinsulinemia of obesity coupled
with inactivation of PTPs may provide sufficient active STAT-5
to promote IGF-1 for increased linear growth in the presence
of relative GH deficiency.
Although the enhanced hepatic insulin-induced STAT-5
pathway exacerbated the development of obesity, our studies
indicate that other pathways might contribute to the enhanced
lipogenesis and steatosis in LTKO mice. We observed elevated
STAT-1 signaling, which can drive PPAR-g gene expression to
promote lipogenesis via SREBP-1c, SCD-1, and ACC, and FFA
uptake via CD36 (Barclay et al., 2011; Matsusue et al., 2003;
Mora´n-Salvador et al., 2011). Thus, the increased steatosis in
LTKO mice might result from the high p-STAT-1, occurring as
a direct consequence of TCPTP deficiency, promoting lipogen-
esis and, at least in female mice, increasing FFA uptake via
CD36. The heightened STAT-3 signaling in LTKO mice might
also contribute to steatosis, since STAT-3 overexpression in-
creases ACC and FAS and inhibits acyl-CoA oxidase (involved
in b-oxidation) expression and promotes steatosis (Kinoshita
et al., 2008). Obesity is associated with systemic inflammation,
and there is evidence for alteration of the inflammatory cytokine
milieu in the livers of obese rodents (Li et al., 2005). Determining
the extent to which TCPTP oxidation/inactivation might exacer-
bate inflammatory STAT-1/STAT-3 signaling in the liver to pro-
mote steatosis will require further study.
The results of this study identify a mechanism for the develop-
ment of selective hepatic insulin resistance, define the contribu-
tions of the insulin-STAT-5 pathway in the liver to the develop-
ment obesity and T2D, and highlight the potential utility of
targeted antioxidants in combating the associated hepatic com-
plications. Many human diseases, including inflammatory and
neurological disorders, cancer, obesity, and T2D, are character-
ized by oxidative stress. Thus the results of this study may have
wide-ranging implications highlighting the potential for oxidative
stress and PTP oxidation to alter cellular signaling in diverse
pathological contexts.
EXPERIMENTAL PROCEDURES
Mice
We maintained mice on a 12 hr light-dark cycle in a temperature-controlled
high-barrier facility with free access to food and water. Age- and sex-matched
mice were used for experiments. Ptpn2lox/lox (C57BL/6) described previously
(Loh et al., 2012; Wiede et al., 2011) were mated with Alb-Cre (C57BL/6)
mice (JAX) for the postnatal deletion of Ptpn2 in hepatocytes. STAT-5lox/lox5 Signaling
from 4 hr fasted mice were processed for immunoblotting.
00 U/ml IL-6, or 100 nM insulin and processed for immunoblotting.
ers from fasted mice were processed for immunoblotting.
for immunoblotting.
nd injected with PBS or insulin, and livers were processed for immunoblotting.
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Figure 7. JI-38 Corrects the Obesity in LTKO
Mice
(A and B) Seven-week-old lox/lox, lox/lox;STAT-5
lox/+, LTKO, and LTKO;Stat-5lox/+micewere HFF for
12 weeks, then fasted overnight, and serum IGF-1
and GH levels (at 8 a.m.) were measured.
(C–E) Seven-week-old female lox/lox and LTKO
mice were HFF for 24 days, administered vehicle or
the synthetic GH releasing hormone agonist JI-38
(50 mg/kg in 100 ml) subcutaneously twice daily (8
a.m. and 6 p.m.) for 20 days, and body weights
were recorded. Serum GH levels (8 a.m.; 30 min
after JI-38) and body composition were deter-
mined. Results are means ± SEM; significance in
(A) and (B) (* LTKO and lox/lox, $ LTKO and lox/
lox;Stat-5lox/+, # LTKO and LTKO;Stat-5lox/+) and
(C) and (D) (* LTKO and lox/lox, # LTKO + JI-38 and
lox/lox) were determined using one-way ANOVA.
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Oxidative Stress and Selective Insulin Resistance(C57BL/6) mice described previously (Cui et al., 2007) were mated with
Alb-Cre;Ptpn2lox/lox mice. Gpx1–/– (C57BL6) mice have been described previ-
ously (Loh et al., 2009). Mice were fed a standard chow or a high-fat diet (23%
fat) as indicated. Experiments were approved by the Monash University
School of Biomedical Sciences Animal Ethics Committee.
Metabolic Measures
Insulin and glucose tolerance tests and hyperinsulinemic-euglycemic clamps
were performed as described previously (Loh et al., 2009). Metabolic mea-
sures were undertaken in an environmentally controlled Comprehensive Lab
Animal Monitoring System (Columbus Instruments) and body composition
was measured by DEXA (Lunar PIXImus2; GE Healthcare).
Cell Culture and RNA Interference
Hepatocytes were isolated by a two-step collagenase A (0.05%w/v; Roche Di-
agnostics) perfusion method as described previously (Fukushima et al., 2010).
Where indicated, cells were serum starved inM199medium for 2–4 hr and then
stimulated with bovine insulin, GH, IFN-g, or IL-6. Alternatively, cells were
treated with 0.5 mM sodium palmitate in the presence of 1% w/v fatty acid-Figure 6. Liver-Specific Stat-5 Heterozygosity Corrects Obesity but Not Steatosis
(A–F) Seven-week-old male lox/lox, Ptpn2lox/lox;Stat-5lox/+ (lox/lox;STAT-5 lox/+), LTKO, and Alb-Cre;Ptpn2lo
12 weeks and body and tissue weights, body composition, and energy expenditure were determined (A); fed
measured (B and C); and livers were extracted for immunoblotting (D), histology (E), or lipid analyses (F). Res
and lox/lox, $ LTKO and lox/lox;STAT-5 lox/+, # LTKO and LTKO;Stat-5lox/+) was determined using a one-wa
Cell Metabolism 20, 8free BSA overnight and then serum starved and
stimulated as indicated. Ptpn2 or Jak-2 was
knocked down transiently in primary murine hepa-
tocytes using Ptpn2- or Jak2-specific siRNAs;
enhanced GFP siRNA was used as a control.
ROS Determinations
H2O2 production in live hepatocytes was deter-
mined using the Amplex Red hydrogen peroxide
assay kit (Invitrogen). Total (GSH) and oxidized
(GSSG) glutathione levels were measured using a
BIOXYTECH GSH/GSSG-412 assay kit (Oxis
International).
PTP Oxidation
Total (reversible and irreversible) PTP oxidation
was assessed essentially as described previously
(Karisch et al., 2011) with some modifications.
Briefly, frozen liver tissue or freshly isolated hepa-
tocytes were homogenized under anaerobic condi-
tions in degassed, ice-cold PTPox lysis buffercontaining 10 mM N-ethylmaleimide to prevent postlysis oxidation and to
alkylate all reduced and active PTPs and incubated for 1 hr at 4C. Cell
lysates and liver homogenates were clarified by centrifugation at 16,000 g
and 50,000 g, respectively, for 20 min, and the buffer was exchanged
(NAP-5 columns, GE Healthcare) with 20 mM HEPES containing 10 mM DTT
to reduce oxidized PTPs. Reduced PTPs were then hyperoxidized to their sul-
fonic (SO3H) state by exchanging the buffer to 20 mM HEPES containing
100 mMpervanadate, resolved by SDS-PAGE, and immunoblotted with PTPox
antibody. Alternatively, pervanadate-treated samples were made to 9 M urea
and 4.5 mM DTT, incubated at 60C for 30 min, and then treated with 10 mM
iodoacetamide before being diluted to a final concentration of 2 M urea for
digestion with TPCK-trypsin (Thermo Scientific) and processing for PTPox
immunoprecipitation and analysis by mass spectrometry as described previ-
ously (Karisch et al., 2011).
Statistical Analysis
Statistical significance was determined by a two-tailed paired Student’s t test
or, where indicated, ANOVA with Bonferroni correction. p values < 0.05 were
considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).x/lox;Stat-5lox/+ (LTKO;Stat-5lox/+) mice were HFF for
and fasted blood glucose and plasma insulin were
ults shown are means ± SEM; significance (* LTKO
y ANOVA (A–C) or a two-tailed Student’s t test (F).
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